[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asymptomatic-carotid-artery-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asymptomatic-carotid-artery-stenosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100503691","canf-comb-ii-pet-mr-in-atherosclerosis-multisite-100503691",false,"NCT05838547","CANF-Comb-II PET-MR in Atherosclerosis Multisite","PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With Cu[64]-25%-CANF-Comb-II","Inclusion Criteria:\n\n* Adults, 18 years of age or older\n* Asymptomatic carotid artery stenosis patients who have undergone carotid Doppler\u002Fultrasound imaging or other carotid imaging which have demonstrated a ≥ 60% diameter carotid artery stenosis.\n* The treating surgeon has planned either treatment with optimal medical therapy (OMT) alone, or OMT and carotid endarterectomy (CEA) surgical intervention.\n\nExclusion Criteria:\n\n* Inability to receive and sign informed consent.\n* Patients with an unstable clinical condition that in the opinion of the Sponsor-Investigator or designee precludes participation in the study.\n* Inability to tolerate up to 60 minutes in a supine position with arms down at sides for PET-MR imaging.\n* Prior history of CEA or carotid artery stent procedure on the ipsilateral side.\n* Past medical history of TIA or stroke within the last 6 months.\n* Unwilling to comply with study procedures and\u002For unable to be available for the duration of the study outlined in the protocol.\n* Contraindications to MR imaging (pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.).\n* Currently pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 64Cu-25%-CANF-Comb or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and\u002For hysterectomy.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn more about plaque biology in asymptomatic carotid artery stenosis (ACAS) patients through imaging. The main questions it aims to answer are:\n\n* To determine the ability of 64Cu-CANF-Comb positron emission tomography (PET) to risk stratify ACAS patients for stroke event, to include transient ischemic attack or remote ipsilateral intervention.\n* To further understand the role of Natriuretic Peptide Receptor C (NPRC) in the evolution of carotid atherosclerosis.\n\nParticipants will be asked to undergo a carotid PET-magnetic resonance imaging (MRI) examination to assess whether the carotid atherosclerosis uptake of 64Cu-CANF-Comb as measured by PET-MRI correlates with patient outcomes (stroke, transient ischemic attack, or remote ipsilateral intervention).",[24,25,26],"Carotid Atherosclerosis","Asymptomatic Carotid Artery Stenosis","Carotid Artery Atheroma",[28,29,30,31],"Stroke","TIA","Vascular Disease","Cardiovascular Disease","RECRUITING","2026-03-19",{"date":35,"type":36},"2026-03-23","ACTUAL",{"date":38,"type":36},"2023-03-21",{"date":40,"type":20},"2027-05-31",{"name":42,"class":43},"Washington University School of Medicine","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100585210","efficacy-and-safety-study-of-endovascular-treatment-of-asymptomatic-carotid-artery-stenosis-100585210","NCT06899399","Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis","Inclusion Criteria:\n\n1. Age 40-80 years\n2. Severe asymptomatic internal carotid artery stenosis (70-99%) confirmed by ultrasound\u002FCTA\u002FDSA\n3. Contralateral ICA stenosis \\\u003C70%\n4. No TIA\u002Fstroke related to target lesion in past 6 months\n5. Declined carotid endarterectomy\n6. Willing to complete 12-month follow-up\n7. Signed informed consent by participant\u002Flegal representative\n\nExclusion Criteria:\n\n1. symptomatic internal carotid artery stenosis in the past 6 months\n2. Spontaneous intracranial hemorrhage in nearly one year\n3. Patients with larger intracranial aneurysms (diameter \\>5 mm) who cannot undergo prior or concurrent treatment\n4. Chronic occlusion without obvious symptoms of cerebral ischemic attack\n5. Patients with transient or permanent neurological deficit resulting from Neurological deficits mimicking TIA\u002Fstroke from TIA or stroke\n6. Common carotid artery ostial lesion\n7. Tandem lesions with severe stenosis of the ipsilateral intracranial artery\n8. Patients with severe dementia\n9. Internal carotid artery dissection\n10. Internal carotid artery aneurysm\n11. Myocardial infarction within 30 days\n12. Ejection fraction \\\u003C30% or New York Heart Association (NYHA) functional class III or higher; unstable angina, characterized by angina at rest with electrocardiogram changes\n13. Cardiogenic embolism, including left ventricular aneurysm, intraluminal filling defects, cardiomyopathy, aortic or mitral valve-prosthetic heart valve, calcified aortic stenosis, infective endocarditis\n14. Mitral stenosis, atrial septal defect, atrial septal aneurysm or left chamber myxoma\n15. Two or more proximal or main coronary artery stenosis 70%, untreated or recanable\n16. Platelets \\\u003C5 \\* 104 \u002F uL, INR\\> 1.5, bleeding time\\> 1min or heparin-related thrombocytopenia; heparin is a contraindication to antiplatelet drugs; coagulopathy\n17. Poor controlled diabetes mellitus, fasting blood glucose\\> 22 mmol\u002FL and ketone body\\>+2\n18. Malignant tumor or respiratory insufficiency, and a life expectancy of \\\u003C5 years\n19. Severe liver and kidney function impairment, ALT\\> 3 times the upper limit of normal value or AST\\> 3 times the upper limit of normal value, blood creatinine increase\\> 2 times the upper limit of normal value\n20. Contrast allergy\n21. Other general anesthesia operations are required during the same period\n22. Pregnant or lactating women\n23. The patient does not attend the clinical trial of other drug or medical device before enrollment\n24. The investigator is not considered fit to participate in this clinical study\n\nImaging exclusion criteria:\n\n1. Type III aortic arch\n2. Severe angulation or tortuosity (≥90 degrees) of the common carotid artery or innominate artery that prevents safe and rapid placement of a guiding catheter or long sheath\n3. Severe angulation or tortuosity of the internal carotid artery that prevents safe deployment of an embolic protection device or stent. Severe tortuosity is defined as the presence of two or more angles ≥90 degrees within 4 cm of the stenotic lesion\n4. Stenosis of the beginning or proximal end of the common carotid artery, innominate artery, distal or intracranial segment of the internal carotid artery, and the stenosis degree is greater than that of the target stenosis\n5. The stenotic lesion exhibits severe circumferential calcification, defined as calcification greater than 3 mm in thickness visible in orthogonal views during fluoroscopy. (Note: In elderly subjects aged ≥70 years, anatomical factors such as tortuosity, arch anatomy, and calcification must be assessed more carefully)","40 Years","80 Years",{"count":53,"type":20},982,"INTERVENTIONAL",[56],"NA","This study is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the safety and efficacy of endovascular stenting combined with optimal medical therapy versus optimal medical therapy alone in patients with asymptomatic severe stenosis (70-99%) of the internal carotid artery. The study plans to enroll 982 patients aged 40-80 years who have had no ipsilateral carotid artery-related neurological symptoms in the past six months and who have declined carotid endarterectomy. The primary endpoints include stroke, myocardial infarction, or death within 30 days post-procedure\u002Fenrollment, as well as the incidence of ipsilateral stroke from 30 days to one year post-procedure\u002Fenrollment. Secondary endpoints include procedural success rate, restenosis rate, changes in cognitive function, and others. The study results will provide high-level evidence-based medical evidence for the treatment selection of patients with asymptomatic carotid artery stenosis.",[25],[60,61,62,63,64,65,66,67],"Asymptomatic carotid stenosis","Carotid stenting","Best medical therapy","Randomized controlled trial","Stroke prevention","Endovascular treatment","Carotid artery disease","Ischemic stroke","2025-03-21",{"date":70,"type":36},"2025-03-28",{"date":72,"type":36},"2024-10-18",{"date":74,"type":20},"2028-07",{"name":76,"class":43},"Beijing Tiantan Hospital",1]